INVEX Therapeutics Ltd (IXC) - Total Liabilities
Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has total liabilities worth AU$176.49K AUD (≈ $124.88K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore INVEX Therapeutics Ltd (IXC) cash conversion ratio to assess how effectively this company generates cash.
INVEX Therapeutics Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how INVEX Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See shareholders equity of INVEX Therapeutics Ltd for net asset value and shareholders' equity analysis.
INVEX Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of INVEX Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cell Impact AB
ST:CI
|
Sweden | Skr29.21 Million |
|
Castelbajac Co. Ltd
KQ:308100
|
Korea | ₩48.08 Billion |
|
DY6 Metals Ltd
AU:DY6
|
Australia | AU$332.27K |
|
Farlim Group (Malaysia) Bhd
KLSE:6041
|
Malaysia | RM37.21 Million |
|
Mountain Province Diamonds Inc
TO:MPVD
|
Canada | CA$650.65 Million |
|
Advent Wireless Inc
V:AWI
|
Canada | CA$2.16 Million |
|
Edgewater Wireless Systems Inc
V:YFI
|
Canada | CA$1.58 Million |
|
Sumber Mas Konstruksi Tbk PT
JK:SMKM
|
Indonesia | Rp5.08 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down INVEX Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IXC stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how INVEX Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for INVEX Therapeutics Ltd (2019–2025)
The table below shows the annual total liabilities of INVEX Therapeutics Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$220.59K ≈ $156.08K |
-48.89% |
| 2024-06-30 | AU$431.63K ≈ $305.41K |
-72.55% |
| 2023-06-30 | AU$1.57 Million ≈ $1.11 Million |
+56.58% |
| 2022-06-30 | AU$1.00 Million ≈ $710.55K |
+52.47% |
| 2021-06-30 | AU$658.61K ≈ $466.01K |
-67.32% |
| 2020-06-30 | AU$2.02 Million ≈ $1.43 Million |
+115.43% |
| 2019-06-30 | AU$935.49K ≈ $661.92K |
-- |
About INVEX Therapeutics Ltd
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II… Read more